Aviation Medicine and Cardiovascular Assessment of Aircrew: A European Society of Cardiology–Aligned Review of Integrating International Civil Aviation Organization, European Union Aviation Safety Agency, Federal Aviation Administration, and Turkish Directorate General of Civil Aviation Aeromedical Standards

Aeromedical certification is based on a safety-first principle: a pilot or other aircrew member must not have a medical disorder that creates an unacceptable risk of sudden or subtle incapacitation during flight. Cardiovascular disease remains one of the most important determinants of flight fitness, as it may impair consciousness, judgment, rhythm stability, exercise capacity, and hemodynamic reserve. Modern aeromedical decision-making therefore requires the integration of aviation law, operational risk, contemporary cardiology guidelines, advanced imaging, biomarkers, and long-term surveillance. The International Civil Aviation Organization (ICAO) Annex 1 provides the global licensing framework; the European Union Aviation Safety Agency (EASA) Part-MED, together with its Acceptable Means of Compliance and Guidance Material, defines detailed operational standards in Europe; and the Federal Aviation Administration (FAA) employs a protocol- and special issuance-based system for many cardiovascular and metabolic disorders. This review summarizes the aeromedical assessment of hypertension, diabetes mellitus, chronic and acute coronary syndromes, heart failure, cardiomy-opathies, arrhythmias and conduction disorders, pacemakers and implantable cardiac devices, valvular heart disease, aortic disease, congenital heart disease, venous throm-boembolism, cardiovascular pharmacotherapy, and major respiratory conditions rel-evant to flight certification. The manuscript is aligned with current European Society of Cardiology cardiovascular guidance and with the operational aeromedical principles applied by ICAO, EASA, FAA, and the Turkish Directorate General of Civil Aviation. In general, preserved ventricular function, absence of significant symptoms, low thrombo-embolic and arrhythmic risk, stable treatment, and adequate exercise capacity support certification or restricted certification. In contrast, uncontrolled hypertension, unstable diabetes, significant residual myocardial ischemia, reduced ejection fraction, malignant ventricular arrhythmias, implantable defibrillator therapy, severe valvular disease, significant aortic pathology, major congenital hemodynamic lesions, or poorly controlled sleep apnea usually preclude certification. Final decisions remain individualized and depend on license class, operational role, treatment burden, surveillance data, and the judgment of the aeromedical authority.